A photo of David Neal Franz.

Founding Director, Tuberous Sclerosis Clinic

Associate Director of Clinical Affairs, Division of Neurology

Professor, UC Department of Pediatrics



Board Certified

Best Doctors logo

My Biography & Research


David Neal Franz, MD, was born and raised in Dayton, Ohio. He received his undergraduate degree in history and literature from Earlham College in Richmond, Indiana.

After completing his training, he served as assistant professor of neurology and pediatrics at Wright State University before returning to Cincinnati Children's Hospital Medical Center.

He established the Cincinnati Tuberous Sclerosis Clinic in 1992, to assist in the medical care of patients who have or are suspected of having tuberous sclerosis.

Additional Languages


Clinical Interests

Tuberous sclerosis (adults and children); neuropharmacology; neurocutaneous disorders; general pediatric neurology

Academic Affiliation

Professor, UC Department of Pediatrics


Neurology, Tuberous Sclerosis, Sturge-Weber Syndrome, Neurology

My Locations

My Education

MD: Ohio State University College of Medicine, Columbus, OH, 1985.

Residency: Wright State University Affiliated Hospitals, Dayton, OH.

Fellowship: Children's Hospital Medical Center, Cincinnati, OH.

Certification: Pediatrics, 1990, 2016; Neurology with special competence in child neurology, 1992.

My Publications

Congenital Lymphatic Malformation and Aortic Aneurysm in a Patient with TSC2 Mutation. Wiemer-Kruel, A; Mayer, H; Ewert, P; Martinoff, S; Eckstein, H; Kriebel, T; Bissler, J; Franz, D; Bast, T. Neuropediatrics: journal of pediatric neurobiology, neurology and neurosurgery. 2020; 51:57-61.

Clinical Letter: A case report of targeted therapy with sirolimus for NPRL3 epilepsy. Vawter-Lee, M; Franz, DN; Fuller, CE; Greiner, HM. Seizure-European Journal of Epilepsy. 2019; 73:43-45.

Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures. Lechuga, L; Franz, DN. Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders. 2019; 19:913-925.

Everolimus for cognition/autism in children with tuberous sclerosis complex Definitive outcomes deferred. Ess, KC; Franz, DN. Neurology. 2019; 93:51-52.

Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Bissler, JJ; Budde, K; Sauter, M; Franz, DN; Zonnenberg, BA; Frost, MD; Belousova, E; Berkowitz, N; Ridolfi, A; Kingswood, JC. Nephrology Dialysis Transplantation. 2019; 34:1000-1008.

Lymphangioleiomyomatosis Mortality in Patients with Tuberous Sclerosis Complex. Zak, S; Mokhallati, N; Su, W; McCormack, FX; Franz, DN; Mays, M; Krueger, DA; Szczesniak, RD; Gupta, N. Annals of the American Thoracic Society. 2019; 16:509-512.

Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis Complex. Peters, JM; Prohl, A; Kapur, K; Nath, A; Scherrer, B; Clancy, S; Prabhu, SP; Sahin, M; Franz, DN; Warfield, SK; et al. Pediatric Neurology. 2019; 90:24-30.

Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. Krueger, DA; Capal, JK; Curatolo, P; Devinsky, O; Ess, K; Tzadok, M; Koenig, MK; Narayanan, V; Ramos, F; Jozwiak, S; et al. European Journal of Paediatric Neurology. 2018; 22:1066-1073.

Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies. Franz, DN; Budde, K; Kingswood, JC; Belousova, E; Sparagana, S; de Vries, PJ; Berkowitz, N; Ridolfi, A; Bissler, JJ. Journal of the European Academy of Dermatology and Venereology. 2018; 32:1796-1803.

Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial. Franz, DN; Lawson, JA; Yapici, Z; Ikeda, H; Polster, T; Nabbout, R; Curatolo, P; de Vries, PJ; Dlugos, DJ; Voi, M; et al. Neurology: Clinical Practice. 2018; 8:412-420.